Heterogeneous response to efgartigimod in real-world experience with myasthenia gravis: Predictors and treatment strategies

Efgartigimod is an established therapy for acetylcholine receptor antibody-positive generalized myasthenia gravis, yet real-world data on long-term overall responsiveness, response patterns, steroid-sparing effects, bridging therapy use, and predictors of benefit remain limited. In this multicenter...

Fuld beskrivelse

Bibliografiske detaljer

Principais autores:	Lior Fuchs, Ifat Vigiser, Hadar Kolb, Keren Regev, Vivian E. Drory, Amir Dori, David Magalashvili, Tal Caller, Gilad Kenan, Yana Mechnik Steen, Mark Hellmann, Adi Wilf-Yarkoni, Tal Friedman Korn, Adi Vaknin-Dembinsky, Alaa Bsoul, Shahar Shelly, Arnon Karni
Format:	Artigo
Sprog:	Inglês
Udgivet:	Elsevier 2026-01-01
Serier:	Neurotherapeutics
Fag:	Generalized myasthenia gravis Efgartigimod Myasthenia gravis activities of daily living (MG-ADL) Prednisone
Online adgang:	http://www.sciencedirect.com/science/article/pii/S1878747926000073
Tags:	Tilføj Tag Ingen Tags, Vær først til at tagge denne postø!